



# HHS Public Access

Author manuscript

*EcoSal Plus*. Author manuscript; available in PMC 2016 November 22.

Published in final edited form as:

*EcoSal Plus*. 2016 November ; 7(1): . doi:10.1128/ecosalplus.ESP-0010-2016.

## Live Attenuated Human *Salmonella* Vaccine Candidates: tracking the pathogen in natural infection and stimulation of host immunity

James E. Galen<sup>1,3,#</sup>, Amanda D. Buskirk<sup>1,2</sup>, Sharon M. Tennant<sup>1,3</sup>, and Marcela F. Pasetti<sup>1,2</sup>

<sup>1</sup>Center for Vaccine Development, Institute for Global Health, University of Maryland School of Medicine, Baltimore MD 21201

<sup>2</sup>Division of Infectious Diseases and Tropical Pediatrics, Department of Pediatrics, University of Maryland School of Medicine, Baltimore MD 21201

<sup>3</sup>Division of Geographic Medicine, Department of Medicine, University of Maryland School of Medicine, Baltimore MD 21201

### Abstract

Salmonellosis, caused by members of the genus *Salmonella*, is responsible for considerable global morbidity and mortality, in both animals and humans. In this review, we will discuss the pathogenesis of *S. Typhi* and *S. Typhimurium*, focusing on human *Salmonella* infections. We will trace the path of *Salmonella* through the body, including host entry sites, tissues and organs affected, and mechanisms involved in both pathogenesis and stimulation of host immunity. Careful consideration of the natural progression of disease provides an important context in which attenuated live oral vaccines can be rationally designed and developed. With this in mind, we will describe a series of attenuated live oral vaccines that have been successfully tested in clinical trials and demonstrated to be both safe and highly immunogenic. The attenuation strategies summarized in this review offer important insights into further development of attenuated vaccines against other *Salmonella* for which live oral candidates are currently unavailable.

### I. Introduction

Salmonellosis, caused by oral infection with members of the genus *Salmonella*, is responsible for considerable global morbidity and mortality, in both animals and humans(1, 2). The genus *Salmonella* contains two species, *S. enterica* and *S. bongori*, each of which contains multiple serotypes of genetically distinct organisms(3). There are currently over 2500 serotypes (referred to as serovars) of *Salmonella* as defined by immunologic identification of somatic O and flagellar H antigens. In turn, *S. enterica* is divided into six subspecies (subsp.), of which only one, *S. enterica* subsp. *enterica* colonizes warm-blooded animals; the remaining subspecies are typically isolated from cold-blooded animals and the environment(3). It was recently reported that, worldwide, the highest morbidities from

<sup>#</sup>Corresponding author: James E. Galen, jgalen@medicine.umaryland.edu.

The authors of this work have no potential conflicts of interest relevant to this review.

human infections resulting from foodborne diseases involved food contaminated with *Salmonella enterica*(1, 2).

In this review, we will focus on *S. enterica* subsp. *enterica*, encompassing the majority of serovars identified thus far, and limit our discussion to vaccine candidates developed to prevent human disease that have been tested in human clinical trials. We will first describe the features of *S. enterica* infections in humans, including the host entry sites, tissues and organs affected, and mechanisms involved in pathogenesis; this information will provide a context for later description of vaccine candidates and the genetic strategies employed to rationally attenuate *Salmonella*. We will then describe general immune responses elicited by natural oral infection with *Salmonella*, and discuss how these responses originate in relation to immunologically primed tissue. Finally, we will present clinical data derived from studies involving *S. enterica* serovars Typhi (the causative agent of typhoid fever) and Typhimurium (which typically causes gastroenteritis in humans). The pathogenic mechanisms explored here for two clinically relevant serovars, and genetic strategies employed to create attenuated but highly immunogenic live oral mucosal vaccines, can be applied to other *Salmonella* serovars for which vaccines are urgently needed(4).

## II. Pathobiology of *Salmonella* infections in humans

### 1. Overcoming the gastric acid barrier

Infection with *Salmonella* is initiated following oral ingestion of contaminated food or water (see Figure 1A). The minimum infectious dose required for establishing a productive infection depends on several key microbiological factors including the strain and serovar of *Salmonella* involved, as well as important host factors including the host mammalian species to be colonized and various gastrointestinal barriers to infection.

In humans, one significant physiological barrier strongly influencing the infectious dose is gastrointestinal acidity. *Salmonella* must overcome potentially lethal levels of inorganic acid (H<sup>+</sup>) which produce a pH as low as 2 in the stomach of healthy adults (Figure 1B)(5). In human challenge studies conducted in the early 1970s at the University of Maryland, ~10<sup>7</sup> colony forming units (CFUs) was the minimum infectious dose required to establish infection in >50% of volunteers orally challenged with a fully virulent *S. Typhi* Quail strain given with milk (6); however, in recent challenge studies conducted at the University of Oxford, using the identical Quail strain administered to volunteers who first ingested bicarbonate solution to neutralize stomach acidity, the dose required to establish infection in >50% of volunteers was reduced by a factor of 4 logs to 10<sup>3</sup> CFUs(7).

Encountering low pH is believed to provide an important environmental signal to *Salmonella* for deploying a cascade of virulence factors necessary for host cell invasion(8). *Salmonella* is equipped with a variety of genetic strategies that contribute to their survival and growth. Two key proteins involved in reallocation of metabolic resources to survive acid stress (called the acid tolerance response; ATR) are RpoS and OmpR. RpoS is an alternate sigma factor used by RNA polymerase to enhance cell survival under acidic conditions by switching RNA transcription and subsequent protein synthesis during exponential growth in nutrient rich conditions to a much slower stationary phase growth in which a variety of acid

resistance genes are induced(8). OmpR is also involved in this ATR, and is the effector component of a two-component environmental sensor, in which the sensor EnvZ activates OmpR upon exposure to both acidity and osmolarity(8). In addition to osmoregulation and acid tolerance, OmpR is also involved in the induction of intracellular survival factors required for survival of *Salmonella* within intracellular vacuoles, following invasion of permissive eukaryotic cells such as macrophages and intestinal epithelial cells(9).

The central role of RpoS in the survival of *Salmonella* has been exploited for the development of live attenuated vaccines against typhoid fever. Several candidate vaccines tested in clinical trials have been engineered from wildtype *S. Typhi* Ty2 strains in which the *rpoS* gene has been naturally inactivated(10). When attenuated vaccine candidates derived from Ty2 were compared to identically attenuated candidates derived from wildtype *S. Typhi* ISP1820 strains, in which *rpoS* was intact, these RpoS+ strains were unacceptably reactogenic(11). It has also been shown that the only licensed and well-tolerated live oral vaccine against typhoid fever, Ty21a, which was created by chemical mutagenesis of Ty2 resulting in multiple attenuating chromosomal lesions, is also deficient in synthesis of RpoS; consequently, this vaccine requires multiple doses to confer protection against disease and displays no acid tolerance response(12).

## 2. Invasion of the small intestine

*Salmonella* organisms that can survive the extreme acidic conditions of the stomach eventually drain into the small intestine, the portal for invasion into deeper tissues and development of systemic disease (Figure 1C). It is at this stage of infection that differences in the serovar-specific progression of disease most clearly manifest themselves. *S. Typhi* possesses several essential clusters of pathogenicity genes, grouped into distinctly regulated chromosomal locations called *Salmonella* pathogenicity islands (SPIs), which enable invading *S. Typhi* organisms to reach deeper tissues of the human liver, spleen, and bone marrow, and bypass innate immunity clearance mechanisms(13, 14). In contrast, *S. Typhimurium* is not equipped with several of these essential intracellular survival mechanisms required for deep penetration of human tissues; therefore, infection of immunocompetent individuals with *S. Typhimurium* typically results only in local tissue invasion and a self-limiting gastroenteritis(13).

It is believed that Peyer's patches are important sites involved in transepithelial migration for *Salmonella* across the luminal surface of the small intestine, based on murine experimental challenge studies with *S. Typhimurium*(15). While direct *in vivo* evidence supporting invasion of Peyer's patches by *S. Typhi* in humans is lacking, several observations support this notion. Examination of intestinal mucosal biopsies from volunteers orally challenged with 10<sup>9</sup> CFUs of the Quail's strain showed granulomatous lesions throughout the small intestine including the duodenum, jejunum, and ileum, accompanied by infiltration of inflammatory cells, and coinciding with systemic clinical symptoms including fever and positive blood cultures(16). Peyer's patches are present throughout the human small intestine, with densities increasing through the jejunum and the largest patches typically residing in the terminal ileum in both children and adults(17, 18), and *Salmonella* is believed

to take advantage of this antigen-sampling compartment of the gastrointestinal tract to invade deeper tissues(19).

In addition to invading Peyer's patches, *Salmonella* are also likely to invade villous epithelial tissue of the small intestine. *Salmonella* are equipped with a molecular arsenal of pathogenicity factors, some of which are common to both serovars Typhimurium and Typhi, enabling rapid and efficient invasion of intestinal epithelial tissues. One critical environmental signal orchestrating a cascade of virulence factors that participate in the invasion process at precisely the right time is osmolarity. Villi of the small intestine possess a gradient of osmolarity which is highest at the luminal surface of villi ( $\sim 700 \text{ mOsm kg}^{-1} \text{ H}_2\text{O}$ ) and decreases to physiological levels ( $\sim 300 \text{ mOsm kg}^{-1} \text{ H}_2\text{O}$ ) in the lower crypts of the villus(20, 21). Incoming luminal *Salmonella* sense the high osmolarity of villus surfaces, which in turn signals induction of a pathogenicity island common to all *Salmonella enterica* serovars capable of infecting mammals, called SPI-1. This locus encodes a type III secretion apparatus which injects effector proteins into target eukaryotic cells, resulting in ruffling of the outer membrane and engulfment of invading bacteria(22).

The transition from extracellular to intracellular pathogen induces an extensive reorganization of both bacterial metabolism and virulence factors. Upon transitioning across the epithelial barrier, the osmolarity of the surrounding tissue drops to physiologic levels, providing a critical signal for *Salmonella* to down-regulate SPI-1 while inducing synthesis of intracellular survival proteins injected into infected cells by a separate and distinct SPI-2 type III secretion system (23). At this stage of infection, crucial genetic differences between invading *S. Typhimurium* and *S. Typhi* begin to strongly influence the course and manifestation of disease(24). Although both serovars possess fully functional SPI-2 and ancillary effector virulence proteins, *S. Typhi* is also equipped with several additional genomic modifications, allowing it to avoid the host natural inflammatory response to invading organisms, which is characterized by a massive and rapid influx of neutrophils; this is not the case for *S. Typhimurium* which causes acute gut inflammation.

*S. Typhi* has been characterized as an excellent example of "reductive genomic evolution" of a human pathogen(25). In contrast to *S. Typhimurium*, *S. Typhi* has evolved to become an exclusive human pathogen, incapable of establishing a productive natural infection in any other mammalian species, and relying on the host to provide multiple essential factors required for survival and growth. In adapting exclusively to infection of humans, *S. Typhi* has naturally accumulated a series of genetic disruptions and inactivations involving approximately 5% of its genome (26). Such inactivations include both loss of metabolic capacity and modifications to the bacterial outer membrane surface that reduce interaction and signaling via Toll-like Receptors (TLRs) expressed by innate immune cells. In contrast, recent data suggest that *S. Typhimurium* may actually benefit from initiation of an inflammatory response because incoming innate immune cells inadvertently generate a critical metabolite called tetrathionate from the oxidative burst; tetrathionate is used exclusively by *S. Typhimurium* as an alternate electron acceptor in anaerobic respiration, and therefore becomes available for enhanced growth prior to excretion from the colon(27, 28). Given that *S. Typhi* spends relatively little time in the intestine prior to invasion and

systemic infection, it comes as no surprise that *S. Typhi* has lost the ability to utilize tetrathionate for anaerobic respiration(29).

Trans epithelial migration and the accompanying drop in osmolarity induces yet another pathogenicity island, exclusive to *S. Typhi*, called SPI-7(30–32), which encodes an outer polysaccharide capsule called Vi(26). The Vi capsule shields lipopolysaccharide (LPS) in the bacterial outer membrane from signaling an inflammatory sensor on the surface of phagocytic cells called Toll-like receptor 4 (TLR4)(33). Signaling of TLR4 induces the secretion of cytokines TNF- $\alpha$  and IL-6, which are responsible for recruitment of neutrophils and other inflammatory cells to the site of infection(13). To further reduce TLR4 interaction and signaling by invading organisms progressing to systemic tissues, *S. Typhi* has acquired an inactivating mutation in *fepE*, a gene controlling the length of the repeating O-antigen comprising *S. Typhi* LPS. The result of losing *fepE* is that synthesis of extremely long LPS (>200 repeat units) is now blocked, and LPS is no longer able to protrude through the protective layer of the Vi capsule(34). Surface expression of the Vi capsule also interferes with neutrophil chemotaxis and phagocytic killing of invading organisms by blocking complement deposition onto the surface of *S. Typhi*; the Vi capsule is composed of a homopolymer of saccharides devoid of free hydroxyl groups required for deposition of the complement component C3b, which in turn activates the complement cascade through the alternative pathway, thereby generating the chemoattractant C5a which attracts neutrophils(35).

Remarkably, the SPI-7 locus also encodes a regulatory protein called TviA, which while up-regulating expression of Vi also down-regulates expression of flagellin(31), another powerful innate signaling protein which binds to and activates TLR5 in the basolateral membrane of intestinal epithelial cells(36, 37). Activation of TLR5 induces secretion of another potent cytokine IL-8, which is also a powerful recruiter of neutrophils and other inflammatory cells to the site of invading pathogens. Importantly, flagellin is not expressed once *S. Typhi* has invaded macrophages, thereby reducing pyroptosis of infected cells and further recruitment of neutrophils(38). This strategy of reducing pyroptosis also prevents release of *S. Typhi* from its protected intracellular niche, thus facilitating systemic dissemination.

### 3. Transient primary bacteremia

Following transit of invading *Salmonella* out of the lumen and across the epithelial barrier of the small intestine, bacteria eventually gain access to the bloodstream for a brief period of time(39), facilitating a more sustained infection of the liver, spleen, and bone marrow (Figure 1D). The passage of bacteria into the bloodstream involves intracellular persistence within human macrophages. The ability of *Salmonella* to survive and replicate within these cells, thereby facilitating systemic infection, clearly differentiates serovar Typhi from Typhimurium. Compared with *S. Typhimurium*, *S. Typhi* has up to 100-fold higher survival rates in elutriated primary human macrophages from peripheral blood, with intracellular replication resulting in very little cell death(40); interestingly, the *rpoS*<sup>+</sup> strain ISP1820 survives better in human macrophages than the *rpoS*<sup>-</sup> strain Ty2(40), again suggesting a role for *rpoS* in host survival.

It has been reported that bacteremia can be detected by the polymerase chain reaction (PCR) in volunteers challenged with the *S. Typhi* Quail's strain within 12 hours after oral ingestion of organisms(41). Culture positive detection of *S. Typhi* is observed in the monocyte fraction of the peripheral blood cells recovered from naturally infected typhoid patients(42). *S. Typhi* is present at very low levels of ~2 CFU/ml in blood from patients with uncomplicated enteric fever during the first week of illness. This level drops to ~1 CFU/ml during the second and third weeks, and declines to ~0.3 CFU/ml during the fourth week; bloodborne *S. Typhi* is not usually present as extracellular organisms, with approximately 63% of viable bacteria residing intracellularly in peripheral blood cells(43). Much higher levels of *S. Typhi* can be detected in the bone marrow of patients with confirmed uncomplicated typhoid fever, with ~5 CFU/ml in bone marrow aspirate recovered in the first week of illness and increasing to ~160 CFU/ml during the third week; again most bacteria are intracellular and therefore less susceptible to antibiotic treatment(44).

#### 4. Establishment of the carrier state and shedding

Invading *S. Typhi* reaching the liver, spleen, and bone marrow can replicate within resident macrophages, and can then be released back into the bloodstream triggering a more substantial secondary bacteremia which precedes the onset of classic typhoid fever(45, 46). However, 2–5% of typhoid cases(47, 48) eventually progress to an asymptomatic chronic infection in which *S. Typhi* can migrate through the hepatic ducts of the liver and into the gall bladder (Figure 1E), setting up a convalescent carrier state in which very high levels of organisms can be intermittently released back into the small intestine, passing through the large intestine (Figure 1F) and being shed in the feces at levels as high as  $10^6 - 10^{10}$  viable organisms per gram of stool (Figure 1G)(49). This intermittent shedding facilitates further spread of the disease to susceptible individuals through contaminated food or water. Chronic infection of the gall bladder is often accompanied by the presence of gallstones, upon which *S. Typhi* are able to establish robust colonization through the formation of biofilms. These biofilms are composed of polysaccharides including Vi and LPS but only minor amounts of flagellar proteins(50). *S. Typhi* residing in biofilms is recalcitrant to antibiotic treatment regardless of the inherent susceptibility of the pathogen. Further direct infection of gall bladder epithelium by free *S. Typhi* growing in the gall bladder lumen can take place via osmotic activation of the SPI-1 invasion locus, resulting in tissue damage and sloughing of epithelial cells down the bile duct and back into the duodenum of the small intestine(51, 52). Interestingly, although acute typhoid fever does not elicit appreciable antibody responses against Vi antigen, chronic carriers are able to mount a very high Vi-specific serum antibody response, which has been shown to be an excellent diagnostic marker for the carrier state(53, 54).

#### 5. Late stage complications and death

Throughout the discussion of *S. Typhi* infections, we have described the pathobiology of acute typhoid fever, without the involvement or influence of life-threatening extraintestinal complications. However, while the vast majority of typhoid cases resolve without life-threatening sequelae, up to 10% of typhoid patients can develop serious complications including death from gastrointestinal hemorrhages and peritonitis from intestinal perforation(39). The rate of intestinal perforations in patients with typhoid fever worldwide

has been estimated to be 3%(55). The average case fatality rate for intestinal perforation was reported to be 15%, with rates as high as 40% depending on geographic location(56). Of note, intestinal perforations usually occur within 45 cm of the ileocecal valve(57), an area with the highest density of Peyer's patches and an important portal of invasion for *S. Typhi*(17, 18).

### III. Strategies for attenuation and design of human live oral *Salmonella* vaccines

#### 1. Immune responses to natural infection

Understanding the progression of human *Salmonella* infections and immune mechanisms that can control infection greatly facilitates the rational design of efficacious live attenuated vaccines against these organisms. Unlike many other enteric pathogens, infection with *Salmonella* does not typically induce a long-lasting protective immunity. Pathogen-specific antibodies, used as readouts of pathogen exposure and immunological priming, are important for clearance only while *Salmonella* is extracellular or within the lumen of the intestines. These antibodies block motility and facilitate complement-mediated lysis or phagocytic killing. Studies in typhoid patients from Bangladesh, where *Salmonella* is endemic, have shown elevated serum IgA and IgG antibodies against LPS, whole-cell extract, and membrane preparations, during infection(58), though membrane preparation-specific IgA antibodies were more prevalent than IgG. These responses are highest in adults, yet children also develop IgA antibodies specific for *S. Typhi* membrane antigens which decline during late convalescence(59).

Though it is evident that both innate and humoral immune responses are required for control of *Salmonella* infections, cellular immunity is believed to play a crucial role in the clearance of *Salmonella* residing intracellularly. However, the exact roles of individual cell types and mechanisms underlying protective immunity remain to be elucidated. Upon infection of phagocytic and professional antigen presenting cells (i.e. macrophages and dendritic cells) *Salmonella* antigens are processed and presented for stimulation of CD4 and CD8 T cells, resulting in activation and differentiation of T helper (Th) 1, Th2 and Th17 cells(60–62), as well as T cytotoxic (Tc)(63, 64) and T regulatory (Treg) cells(65), which are believed to be essential for protection against disease (66). Natural infection also results in the induction of Th1 type CD4+ and CD8+ T cells that produce high levels of IFN- $\gamma$  during acute and convalescent phases of infection(60). Peripheral blood cells isolated from typhoid patients and stimulated with bacterial antigens produced higher levels of other cytokines including IFN- $\gamma$ , MIP-1 $\beta$ , sCD40L, TNF- $\beta$ , IL-13, and IL-9 during convalescence, which are likely required for an effective immune response that leads to bacterial clearance(62). Recent studies have also shown that natural infection results in the upregulation of the gut-homing integrin  $\alpha$ 4 $\beta$ 7 on T regulatory cells (65), which may play a role in downregulating proinflammatory CD4 and CD8 T cell responses.

#### 2. General strategies for live oral vaccine design

As discussed above, *Salmonella* possess specialized virulence mechanisms that allow them to reach permissive niches within the human host, establishing reservoirs for subsequent

replication. Therefore, genetically inactivating one or more of these essential virulence factors constitutes one highly successful approach for weakening fully virulent organisms and constructing attenuated live *Salmonella* vaccines intended for oral immunization of humans. A more subtle but equally effective strategy for attenuating pathogens targets metabolic pathways required to sustain infection in the host, but this approach must be accomplished in such a way that the resulting live vaccine remains metabolically fit enough to reach immune inductive sites and elicit biologically relevant protective immunity in the absence of overt disease. Over-attenuation of a candidate vaccine, while resulting in a highly safe and non-reactogenic organism, will require the administration of multiple oral doses to achieve protective immunity, a requirement that complicates deployment of the vaccine into the field. These key concepts for designing live oral vaccine candidates are particularly well illustrated with a select group of attenuated candidate live oral vaccines that are summarized in Table 1 and individually examined in detail below.

### 3. Chemical mutagenesis and Ty21a

The only licensed vaccine against human infections caused by *Salmonella* is Ty21a, a typhoid fever vaccine derived from the parental wildtype *S. Typhi* strain Ty2 by chemical mutagenesis using N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(67). MNNG is an alkylating agent that induces transition mutations (purine to purine or pyrimidine to pyrimidine base transitions) in replicating DNA, causing pleiotropic mutations to arise in multiple genes which can affect a wide variety of unrelated cell functions(68). Consequently, sequencing of the chromosome of Ty21a has revealed that this vaccine contains multiple mutations in a metabolic pathway controlling the incorporation of galactose into properly synthesized LPS(69). Ty21a requires growth in the presence of trace amounts (0.001%) of galactose in order to synthesize full-length LPS, but growth in the presence of higher concentrations (0.1%) leads to the intracellular accumulation of toxic intermediates that causes premature lysis of the vaccine strain(69). Ty21a contains additional metabolic mutations in amino acid synthesis pathways, leading to a requirement for isoleucine and valine (in addition to tryptophan and cysteine inherited from the parent strain Ty2) for growth under nutrient limiting conditions(69).

As a result of multiple mutations in critical metabolic pathways, Ty21a grows slower than the wildtype Ty2 *in vitro*(67), and cannot be recovered from the small intestine of orally vaccinated humans regardless of the number of organisms or vaccine doses administered(70). For this reason, successful oral immunization of humans requires a minimum of 3 doses to provide durable protection against challenge, with efficacy also depending on growth conditions and specific formulation of the vaccine. Ty21a grown in the absence of galactose results in a rough vaccine strain lacking O-antigen that was poorly immunogenic and failed to protect volunteers challenged with  $10^5$  CFUs of the Quail's strain(70). In contrast, 3 oral doses of O-expressing Ty21a, administered orally every other day in enteric-coated capsules, conferred 62% protection in field trials over a seven year period; 3 doses of a liquid formulation, reconstituted from buffered lyophilized sachets, elicited 78% protection over a 5 year period(71). These data support the hypothesis that O antigen-specific immunity plays an important role in protection against typhoid fever. Interestingly, the recurrence rate for exposed individuals who recovered from a previous



episode of typhoid fever ranged from 20% in an endemic region(72) to 23% in convalescent volunteers challenged with  $10^5$  CFUs of the Quailles strain(73), suggesting that natural infection does not necessarily elicit the robust protective immune effector mechanisms against re-infection as observed in vaccinees receiving multiple oral doses of Ty21a.

Both serum antibody titers and the frequency of circulating antibody secreting cells (ASCs) have historically been the primary method to ascertain immunogenicity of orally delivered live *Salmonella* vaccines(74). The B cell responses induced by Ty21a include LPS-specific serum IgG and IgA antibodies(75) and mucosally primed ASCs bearing the  $\alpha 4\beta 7$  gut homing integrin(76). Among individuals who received the routine 4 doses of Ty21a in the US, half of recipients developed strong anti-LPS IgA B memory responses and 30–40% developed anti-flagella IgG and IgA B memory responses(77). Ty21a-induced antibodies have been shown to bind to *S. Typhi* and enhance phagocytosis and bactericidal activity(75, 78).

Ty21a has also been shown to induce IFN- $\gamma$ -producing CD4 and CD8 T terminal effector memory cells expressing  $\alpha 4\beta 7$ (79). PBMCs from Ty21a vaccinated volunteers stimulated with *S. Typhi* flagella produced cytokines required for clearance of intracellular pathogens and cell-mediated cytotoxicity including IFN- $\gamma$ , TNF $\alpha$ , IL-1 $\beta$ , IL-6, and IL-10(80). In an early study, >90% of Ty21a vaccinated volunteers developed LPS- and flagella-specific antibodies (78). Interestingly, when *Salmonella*-specific IgA antibodies were incubated together with CD4 T cells, antibody-dependent cellular cytotoxicity was observed against infected cells (81). Ty21a vaccination has also been shown to elicit IFN- $\gamma$ -secreting CD8 T cells that exhibited cytotoxic activity against infected cells(82–84). Further analysis showed that the vaccine-induced CD8 T cells were long-lived memory cells with the capacity to produce multiple cytokines including IFN- $\gamma$ , TNF $\alpha$ , IL-2, and IL-17(64, 85). Taken together, these data suggest that, in contrast to natural infection, repeated vaccination with Ty21a appears more effective than wildtype organisms at presenting a variety of otherwise immunologically muted antigens such as LPS, flagella, and other outer membrane proteins to the immune system, thereby resulting in robust pathogen-specific humoral and cellular immunity.

#### 4. Genetically engineered vaccines with mutations in *rpoS*

In addition to mutations in genes controlling the synthesis of tryptophan and cysteine, the parent strain Ty2 used to create the vaccine Ty21a also contains a naturally occurring mutation inactivating *rpoS*(10, 86). The role of *rpoS* in adapting to environmental stresses, including its role in the acid tolerance response, was previously described above in the pathobiology of *Salmonella* infections. However, *rpoS* also regulates the synthesis of Vi capsular polysaccharide(87, 88), which plays a critical role in the systemic survival of invading *S. Typhi* in natural disease. 99.5% of 2,222 *S. Typhi* bloodborne clinical isolates express the Vi polysaccharide(89), and human clinical trials clearly demonstrate that Vi<sup>+</sup> wildtype *S. Typhi* challenge strains are more virulent than Vi<sup>-</sup> strains(6). However, in other studies, 36% (15/41) of *S. Typhi* clinical isolates were proven to carry defective *rpoS* alleles; interestingly, no inactivating mutations were identified in *S. Typhimurium* clinical isolates(86), suggesting different roles for *rpoS* in the physiology and resulting pathogenic

potential of *S. Typhimurium* versus Typhi in humans. It has also been shown *in vitro* that RpoS<sup>-</sup> strains such as Ty2 express more Vi capsular antigen than wildtype RpoS<sup>+</sup> strains under inducing osmolarity conditions (87, 88). The picture that emerges is that under the high osmolarity conditions of the intestinal lumen, *rpoS* is up-regulated, which represses synthesis of Vi; this negative control is further strengthened by the osmotic repression of *tviA* which is a positive activator of Vi synthesis. Since these conditions induce SPI-1 and the invasion of the small intestine, transepithelial migration results in a reduction of osmolarity to physiological levels, thereby repressing *rpoS* and activating *tviA* for induction of Vi synthesis (Figure 2).

It is therefore plausible that although RpoS<sup>-</sup> strains are attenuated with respect to survival in environmentally stressful conditions such as intragastric acidity (controlling successful passage into the small intestine), vaccines derived from the RpoS<sup>-</sup> Ty2 parent might nonetheless be more immunogenic versus isogenic RpoS<sup>+</sup> strains because of better intracellular survival within macrophages, allowing invading organisms to penetrate deeper into the host and reach immune inductive sites at levels high enough to elicit protective immunity. However, this hypothesis was recently shown to be incorrect in a Phase 1 clinical trial in which volunteers were orally immunized with a single dose of 10<sup>10</sup> CFUs of two isogenic vaccine strains derived from Ty2 ( $\chi$ 9639 and  $\chi$ 9640, Table 1)(61, 90), one carrying the original mutated *rpoS* allele and the other carrying a genetically engineered wildtype *rpoS* allele. Although not achieving statistical significance, a trend for higher serum IgA and IgA antibody secreting cells (ASCs), specific for *S. Typhi* surface antigens, was observed for RpoS<sup>+</sup> vaccines versus RpoS<sup>-</sup> strains(90). Interestingly, a third arm of this study was included in which volunteers were orally vaccinated with 10<sup>10</sup> CFUs of an identically attenuated *S. Typhi* vaccine strain, derived from ISP1820 and designated  $\chi$ 9633, which carried the endogenous wildtype allele of RpoS. One subject from this group had a single positive blood culture 5 days following vaccination which spontaneously resolved without clinical intervention(90). These results seem to suggest an important role for RpoS in the early stages of vaccination with attenuated strains of *S. Typhi*, in which limited invasion of the host must be carefully balanced by additional chromosomal mutations in engineered vaccine strains to ensure both safety and immunogenicity. It is likely that the candidate vaccines included in this study may have proven more immunogenic if given in more than a single dose. Nonetheless, it was concluded from this trial that future vaccine development by this group would focus on RpoS<sup>+</sup> Ty2 derivatives.

### 5. Engineered vaccines with deletions blocking systemic infection: *phoPQ*

The licensed and experimental vaccines discussed thus far have relied upon interference of essential metabolic pathways for construction of safe live oral vaccines. However, careful selection of virulence factors for inactivation can also yield safe vaccines that are highly immunogenic. PhoP/PhoQ is a pleiotropic two-component signal transduction system in which the environmental sensor PhoQ (activated either by low pH or low concentrations of extracellular Mg<sup>2+</sup>) triggers the transcriptional regulator PhoP to induce the synthesis of the SPI-2 locus controlling intracellular survival functions(91). In addition, PhoP/PhoQ regulates expression of other genes within unlinked pathogenicity islands such as SPI-11, in which the *pagC* gene is involved with intracellular survival of *Salmonella* within

macrophages(92, 93). Therefore, inactivation of PhoP/PhoQ would be expected to interrupt the systemic phase of *Salmonella* infection. When this attenuating strategy was used as the sole means for construction of a single dose live oral typhoid vaccine, again derived from the parent strain Ty2 and designated Ty800 (Table 1), the resulting candidate vaccine was shown in Phase 1 clinical trials to be safe, well-tolerated, and immunogenic after single oral doses of up to  $10^{10}$  CFUs(94). Humoral immunity was comparable to responses from a second cohort of the study receiving 4 doses of Ty21a, and robust dose-dependent *S. Typhi* LPS-specific IgA-secreting cell responses were detected in 10 of 11 subjects(94).

Given that the PhoP/PhoQ regulon is highly conserved between the serovars Typhi and Typhimurium, construction and initial clinical testing of Ty800 offered an intriguing opportunity to specifically investigate the immunogenicity in humans of two closely related serovars of *Salmonella* (i.e Typhi versus Typhimurium) in which systemic dissemination of the organism was now blocked in both cases, and observed immunogenicity would therefore theoretically depend only on local immune induction sites. Two parallel Phase 1 studies were performed in which *S. Typhi* Ty1033 and Typhimurium LH1160 candidate vaccine strains (Table 1), similarly deleted for PhoP/PhoQ, were administered to volunteers, with subjects vaccinated orally with *S. Typhi* Ty1033 receiving  $10^{10}$  CFUs(95) and those vaccinated with *S. Typhimurium* LH1160 receiving an oral dose of  $5-8 \times 10^7$  CFUs(96). As expected, no bacteremia was observed for either serovar, and both vaccines were highly immunogenic with no adverse reactions. However, despite the fact that subjects immunized with the attenuated *S. Typhimurium* vaccine received a 3 log unit lower dose of vaccine than those vaccinated with attenuated *S. Typhi*, 3 of 6 volunteers were durably colonized and excreted vaccine organisms for up to 10 days(96). Despite the absence of clinical symptoms, volunteers vaccinated with LH1160 were treated prophylactically with antibiotics to hasten complete elimination of this *S. Typhimurium* vaccine. In contrast, shedding of *S. Typhi* Ty1033 vaccine organisms was limited to no longer than 4 days in 9 of 9 volunteers, requiring no therapeutic intervention with antibiotics. Interestingly, volunteers more durably colonized with the *S. Typhimurium* vaccine mounted the most robust vaccine-specific humoral (anti-LPS serum IgA and IgG) and mucosal (anti-LPS ASCs) immune responses. Only 1 of 6 subjects immunized with *S. Typhimurium* LH1160 failed to mount significant mucosal or serological responses against any serovar Typhimurium antigens, but this subject only excreted vaccine organisms for 2 days, suggesting that prolonged intestinal colonization can enhance immunogenicity(96). This surprising difference in fecal shedding of vaccine organisms seems to underscore the fact that *S. Typhimurium* is metabolically adapted to survival and growth within the human intestinal tract, whereas *S. Typhi* spends relatively little time in this environment as it quickly invades into deeper and more permissive tissues of the human host.

## 6. Engineered vaccines with deletions blocking systemic infection: *ssaV*

A similar study design was pursued in a separate investigation, this time involving a direct comparison in a single Phase 1 clinical trial of identically attenuated *S. Typhi* versus *S. Typhimurium* vaccines, in which a more narrowly focused deletion in *ssaV* targeted only the SPI-2 secretion apparatus to again interrupt systemic dissemination (Table 1). In this study, 18 volunteers were randomly assigned to two groups and orally immunized with a single

escalating dose of either *S. Typhi* vaccine M01ZH09 or *S. Typhimurium* vaccine WT05, in doses ranging from  $10^7$  to  $10^9$  CFUs(97). Importantly, both vaccines also carried an additional metabolic deletion mutation in the *aroC* gene encoding chorismate synthase, rendering both strains auxotrophic for the biosynthesis of aromatic amino acids(98). As with the PhoP/PhoQ vaccines, no bacteremia was observed after vaccination with either serovar, and both vaccines were highly immunogenic with no adverse reactions. However, prolonged excretion of vaccine organisms for 12–23 days was again observed in 5 of 6 subjects receiving either  $10^8$  or  $10^9$  CFUs of the *S. Typhimurium* vaccine, regardless of the engineered auxotrophy for aromatic amino acids(97). Despite the limitation of these amino acids within the tissues of human hosts, enough of these nutrients are freely available within the lumen of the intestinal tract to support extended growth and excretion of *S. Typhimurium* vaccines. Therefore, this strategy for metabolic attenuation does not by itself ensure sufficient attenuation for *S. Typhimurium* vaccines.

However, the *S. Typhi* vaccine M01ZH09, which carries only these two deletion mutations in *aroC* and *ssaV*, has been shown to elicit excellent mucosal and humoral immunity. Next to Ty21a, M01ZH09 is the most extensively evaluated typhoid vaccine to date, having successfully completed four Phase 1 clinical trials and two Phase 2 clinical trials, involving a total of 356 orally immunized subjects from North American, Europe, and endemic Asian populations(97, 99–102). The vaccine given orally as a single dose of up to  $10^{10}$  CFUs is safe, causes no bacteremia, and engenders both mucosal and serum antibody responses comparable to those observed in individuals immunized with 3 doses of Ty21a, with aggregate *S. Typhi* LPS-specific seroconversions between 50% and 92% for M01ZH09 versus 50–64% for Ty21a and LPS-specific ASCs in 90–100% of vaccinees receiving M01ZH09 versus 63–96% for Ty21a(102).

## 7. Engineered vaccines with deletions blocking systemic infection: *htrA*

Engineered auxotrophic dependence on supplementation with aromatic amino acids for growth was also exploited in another successful live oral typhoid vaccine that underwent three iterations of refinements, each tested in Phase 1 or Phase 2 clinical trials to guide further development (Table 1). CVD 908 was first engineered from wildtype Ty2 to carry deletion mutations in *aroC* (encoding chorismate synthase) and *aroD* (encoding 3-dehydroquinate dehydrogenase), two independent non-reverting mutations in the essential aromatic amino acid biosynthesis pathway(11, 98). Following a single oral dose of CVD 908, the majority of vaccine recipients responded with LPS-specific serum IgG (83%) and all of them with LPS-specific IgA ASCs(103). In the presence of *S. Typhi* flagella and killed organisms, PBMCs from vaccinated individuals proliferated and produced IFN- $\gamma$  and IL-6 indicative of a Th1 type/proinflammatory response(104). However, despite the presence of two distinct deletion mutations in *aroC* and *aroD* (plus the *rpoS* mutation from Ty2), vaccine organisms were still able to cross the intestinal epithelial barrier and were detected in the blood of vaccinees receiving oral doses as low as  $5 \times 10^7$  CFUs(105). Therefore, it was deemed prudent to engineer additional chromosomal deletions to prevent this self-limiting bacteremia, even though no symptoms were documented in any of these volunteers and no therapeutic intervention was required.

The resulting candidate vaccine, CVD 908-*htrA*, contained a new deletion in *htrA* encoding a heat shock protease(105); previous data obtained *in vitro* with *S. Typhimurium* suggested that *htrA* enhanced survival within macrophages(106), and thus deletion of this gene might therefore limit systemic spread of the vaccine. Indeed, Phase 1 clinical trials of CVD 908-*htrA* conclusively demonstrated that the desired balance between reactogenicity and immunogenicity had been achieved. No vaccine organisms were detected in the blood and limited shedding of vaccine organisms for less than 3 days was seen in volunteers orally vaccinated with up to  $5 \times 10^9$  CFUs of freshly harvested organisms. In addition, excellent mucosal, humoral, and cellular immune responses were observed. 100% (15/15) of volunteers vaccinated with  $5 \times 10^8$  or  $5 \times 10^9$  CFUs seroconverted to serum IgG against *S. Typhi* LPS and 11/15 (73%) against flagella. IgA anti-LPS ASCs were detected in all vaccinees receiving  $5 \times 10^8$  or  $5 \times 10^9$  CFUs as well, and lymphoproliferative responses against flagella or inactivated whole cell antigen were detected in 69% (9/13) and 77%(10/13) of subjects, respectively(105). Interestingly, when lyophilized vaccine was further tested in Phase 2 clinical trials, mucosal ASC responses were maintained (94–100% LPS-specific ASCs and 50–82% flagella-specific ASCs) at doses of  $4.5 \times 10^8$  CFUs (the highest dose given orally), but serum antibody responses declined slightly with only 49% of volunteers mounting anti-LPS IgG responses and 41% generating anti-flagella responses; 63% of vaccinees had lymphoproliferative responses to flagella and 44% responded to particulate inactivated whole cell(107).

CVD 908-*htrA* was then further genetically modified to constitutively express Vi polysaccharide(108). This novel approach was based on a hypothesis proposed by Levine et al., who observed that Ty21a live oral vaccine and a subunit parenteral vaccine comprised of purified Vi polysaccharide both confer substantial protection against typhoid disease after multiple doses, despite the fact that Ty21a does not synthesize Vi polysaccharide and that the purified Vi vaccine is a monovalent vaccine lacking other surface antigens from *S. Typhi*(108). This suggested that immunity to typhoid disease may be manifested by at least two distinct immune mechanisms, one involving targeted antibody responses against Vi and the other involving more broad humoral and cell-mediated immunity against *S. Typhi* surface antigens other than Vi. Given that all genetically engineered live oral vaccines tested in clinical trials to date have elicited very poor serum immunity to Vi, Levine et al. proposed that perhaps a more broadly immunogenic vaccine could be developed, eliciting immunity against surface antigens including Vi, by further engineering constitutive expression of Vi in CVD 908-*htrA*.

To accomplish this, the powerful constitutive promoter  $P_{tac}$  was used to replace the highly regulated and osmotically controlled  $P_{viA}$  promoter controlling expression of the Vi operon *viaB* encoded within the SPI-7 pathogenicity island. It was then confirmed *in vitro* that excellent expression of Vi antigen in the resulting vaccine candidate CVD 909 (Table 1) was now independent of osmotic induction. Interestingly, it was also demonstrated that CVD 909 was less invasive for Henle 407 cells, a human embryonic intestinal epithelial cell line, than the parent CVD 908-*htrA* at low osmolarity(108); this observation agrees with previously published *in vitro* data in which induced high-level expression of Vi polysaccharide by osmotic induction of wildtype *S. Typhi* Ty2 significantly reduced invasion of intestinal epithelial cells(109).

CVD 909 proved to be safe and immunogenic in Phase 1 clinical trials despite over-expression of the Vi polysaccharide virulence factor(77, 110). However, serum antibody responses against *S. Typhi* LPS and flagella were lower when compared to the parent vaccine CVD 908-*htrA*. Only 2/6 (33%) volunteers orally vaccinated with a single dose of  $2.5 \times 10^9$  freshly harvested vaccine organisms mounted anti-LPS IgG serum antibody responses(110) versus 8/8 vaccinated with a 10-fold lower dose of  $5 \times 10^8$  CFUs of CVD 908-*htrA*(105); similarly, only 1/6 CVD 909 vaccinated subjects had anti-flagellar serum IgG antibody responses versus 6/8 for CVD 908-*htrA*. This reduction in surface antigen-specific antibody responses is consistent with strong expression of the regulator TviA, which down-regulates flagellar expression while up-regulating synthesis of Vi capsule to mask surface LPS(31, 38). Curiously, despite over-expression of the capsular polysaccharide in CVD 909, Vi-specific serum immune responses were not observed(110).

In a subsequent clinical trial, volunteers primed with a single oral dose of  $5 \times 10^9$  CFUs of CVD 909 and boosted intramuscularly with 25  $\mu$ g of the licensed Vi polysaccharide vaccine Typhim@Vi, did not have significantly elevated Vi-specific IgM, IgG, or IgA antibodies above volunteers who received a placebo prime and boost with Typhim@Vi (77). 64% of the CVD909 recipients developed anti-LPS serum IgG and IgA while only 18–27% developed anti-flagella serum antibodies(77). Importantly, these antibodies exhibited functional opsonophagocytic activity against wild-type *S. Typhi*(75). Over half (55%) of CVD909 primed individuals developed anti-Vi IgA B memory cells, compared to 12.5% in the placebo primed group. This vaccine strain also resulted in the production of anti-flagellar IgA B memory cells that remained for at least 1 year post-vaccination(77). It remains puzzling that no Vi-specific antibody responses were observed in subjects primed with a Vi over-expressing live vaccine prior to boosting with a purified Vi subunit vaccine. The fact that robust Vi-specific antibody responses are observed in asymptomatic human carriers chronically colonized with *S. Typhi* underscores the fact that much still remains to be elucidated regarding induction of protective immunity against *Salmonella* and how to exploit this information in the rational design of efficacious live oral vaccines.

#### IV. Conclusions and future directions

Herein, we have summarized the pathogenesis of human *Salmonella* infections, contrasting serovars Typhi and Typhimurium with regard to niches colonized and immune responses elicited by wildtype organisms. Understanding the natural progression of disease provides an important context in which attenuated live vaccines can be rationally designed and developed. With this in mind, we have reviewed a series of attenuated live vaccines which have been tested in clinical trials, and demonstrated to be both safe and highly immunogenic in the case of *S. Typhi* typhoid vaccines. However, we have also pointed out that correlates of protection against enteric fever have yet to be adequately defined. Therefore, at this point immune responses elicited by candidate vaccines remain only suggestive of protective efficacy in the absence of challenge studies conducted with vaccinated volunteers. However, it is encouraging that a human typhoid challenge model has now been re-established(7), offering the opportunity to compare the various attenuation strategies for currently available *S. Typhi* vaccine candidates, and their ability to induce immune responses that can protect against disease. Given the paucity of data relevant to mechanisms involved in disease

clearance, it is entirely possible that some vaccines clinically proven to be safe and highly immunogenic will nonetheless fail to offer significant protection when administered orally as a single dose. Such future challenge studies may specifically inform the development of more efficacious vaccine schedules involving two or more doses, without having to re-engineer further vaccine candidates, to elicit durable protective immunity.

Although there are now multiple examples of attenuated oral *S. Typhi* vaccines that have been clinically demonstrated to be safe and immunogenic, all *S. Typhimurium* vaccine candidates tested to date displayed unacceptable safety profiles, with prolonged colonization of human volunteers leading to unacceptable shedding of viable vaccine organisms over several weeks(96, 97). It became evident from these important studies that strategies proven successful for attenuation of *S. Typhi* do not necessarily guarantee success when applied to *S. Typhimurium*. This is undoubtedly related, at least in part, to the differences in metabolic niches exploited by these two serovars, with *S. Typhimurium* typically thriving extracellularly in the gastrointestinal lumen while *S. Typhi* proliferates intracellularly in deeper tissues of the host. However, the pathogenicity of *S. Typhimurium* has recently been changing, with more invasive and multidrug-resistant strains being increasingly isolated from the blood of malnourished children and immunocompromised adults living in sub-Saharan Africa(111–113). These newly emerging strains have developed an improved ability to replicate within human macrophages while down-regulating production of flagella to reduce innate immune recognition(114). With this unsettling rise in unconventional invasive non-typhoidal *Salmonella* (iNTS) strains, it may therefore be appropriate to revisit available attenuated *S. Typhimurium* vaccines with the goal of improving the safety of existing vaccine candidates. We recognize, however, that while development of improved second generation *S. Typhimurium* live vaccines might prove to be safe and highly immunogenic in developed countries, they could nonetheless prove to be far less immunogenic in endemic regions of developing countries where malnourished children and immunocompromised adults suffering from co-infection with malaria parasites or HIV would be severely compromised for humoral and cell mediated immunity(112). Notwithstanding this caveat, it would be intriguing to target the intestinal proliferation of *S. Typhimurium* to reduce or eliminate the unacceptable shedding of vaccine organisms. In theory, this might be accomplished by inactivating the ability to exploit tetrathionate as an alternate electron acceptor for anaerobic respiration, thereby eliminating the metabolic advantage of *S. Typhimurium* over competing flora to enhance clearance and reduce unacceptably high levels of shedding(27, 28). Another possible approach could involve introduction of proven attenuation strategies into an iNTS isolate of *S. Typhimurium*, with further deletion of a novel invasion gene called *st313-td*, recently reported to enhance systemic invasion in experimental animal models of infection(115). We conclude that the attenuation strategies we have summarized offer important insights into further development of attenuated *S. Typhimurium* vaccines, as well as for other serovars for which vaccines are currently unavailable.

## Acknowledgments

This work was supported by several grants from the National Institutes of Health, National Institute of Allergy and Infectious Disease; SMT was supported by NIH, NIAID U19 AI109776-01 (Project 4); MFP was supported by

NIH, NIAID R01 AI089519; and JEG was supported by NIH, NIAID R01 AI095309. The graphic elements for Figures 1 and 2 were provided by Timothy Phelps, Department of Art as Applied to Medicine, Johns Hopkins University.

## References

1. Kirk MD, Pires SM, Black RE, Caipo M, Crump JA, Devleeschauwer B, Dopfer D, Fazil A, Fischer-Walker CL, Hald T, Hall AJ, Keddy KH, Lake RJ, Lanata CF, Torgerson PR, Havelaar AH, Angulo FJ. World Health Organization Estimates of the Global and Regional Disease Burden of 22 Foodborne Bacterial, Protozoal, and Viral Diseases, 2010: A Data Synthesis. *PLoS Med.* 2015; 12:e1001921. [PubMed: 26633831]
2. Kirk MD, Pires SM, Black RE, Caipo M, Crump JA, Devleeschauwer B, Dopfer D, Fazil A, Fischer-Walker CL, Hald T, Hall AJ, Keddy KH, Lake RJ, Lanata CF, Torgerson PR, Havelaar AH, Angulo FJ. Correction: World Health Organization Estimates of the Global and Regional Disease Burden of 22 Foodborne Bacterial, Protozoal, and Viral Diseases, 2010: A Data Synthesis. *PLoS Med.* 2015; 12:e1001940. [PubMed: 26701262]
3. Grimont, PAD.; Weill, F-X. Antigenic formulae of the *Salmonella* serovars. In *Salmonella*. 9th. WCCfRaRo. , editor. Paris, France: Institute Pasteur; 2007.
4. Tennant SM, Levine MM. Live attenuated vaccines for invasive *Salmonella* infections. *Vaccine.* 2015; 33(Suppl 3):C36–C41. [PubMed: 25902362]
5. Verdu E, Viani F, Armstrong D, Fraser R, Siegrist HH, Pignatelli B, Idstrom JP, Cederberg C, Blum AL, Fried M. Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites, and N-nitroso compounds. *Gut.* 1994; 35:455–460. [PubMed: 8174980]
6. Hornick RB, Greisman SE, Woodward TE, DuPont HL, Dawkins AT, Snyder MJ. Typhoid fever: pathogenesis and immunologic control. *N. Engl. J. Med.* 1970; 283:686–691. [PubMed: 4916913]
7. Waddington CS, Darton TC, Jones C, Haworth K, Peters A, John T, Thompson BA, Kerridge SA, Kingsley RA, Zhou L, Holt KE, Yu LM, Lockhart S, Farrar JJ, Szein MB, Dougan G, Angus B, Levine MM, Pollard AJ. An outpatient, ambulant-design, controlled human infection model using escalating doses of *Salmonella* Typhi challenge delivered in sodium bicarbonate solution. *Clin. Infect. Dis.* 2014; 58:1230–1240. [PubMed: 24519873]
8. Audia JP, Webb CC, Foster JW. Breaking through the acid barrier: an orchestrated response to proton stress by enteric bacteria. *Int. J. Med. Microbiol.* 2001; 291:97–106. [PubMed: 11437344]
9. Garmendia J, Beuzon CR, Ruiz-Albert J, Holden DW. The roles of SsrA-SsrB and OmpR-EnvZ in the regulation of genes encoding the *Salmonella typhimurium* SPI-2 type III secretion system. *Microbiology.* 2003; 149:2385–2396. [PubMed: 12949164]
10. Robbe-Saule V, Norel F. The *rpoS* mutant allele of *Salmonella typhi* Ty2 is identical to that of the live typhoid vaccine Ty21a. *FEMS Microbiol. Lett.* 1999; 170:141–143. [PubMed: 9919662]
11. Tacket CO, Hone DM, Curtiss R Iii, Kelly SM, Losonsky G, Guers L, Harris AM, Edelman R, Levine MM. Comparison of the safety and immunogenicity of *aroC aroD* and *cya crp Salmonella typhi* strains in adult volunteers. *Infect. Immun.* 1992; 60:536–541. [PubMed: 1730487]
12. Hone DM, Harris AM, Levine MM. Adaptive acid tolerance response by *Salmonella typhi* and candidate live oral typhoid vaccine strains. *Vaccine.* 1994; 12:895–898. [PubMed: 7975830]
13. Tsolis RM, Young GM, Solnick JV, Baumler AJ. From bench to bedside: stealth of enteroinvasive pathogens. *Nature reviews. Microbiology.* 2008; 6:883–892. [PubMed: 18955984]
14. Keestra-Gounder AM, Tsolis RM, Baumler AJ. Now you see me, now you don't: the interaction of *Salmonella* with innate immune receptors. *Nature reviews. Microbiology.* 2015; 13:206–216. [PubMed: 25749454]
15. Jones BD, Gori N, Falkow S. *Salmonella typhimurium* initiates murine infection by penetrating and destroying the specialized epithelial M cells of the Peyer's patches. *J. Exp. Med.* 1994; 180:15–23. [PubMed: 8006579]
16. Sprinz H, Gangarosa EJ, Williams M, Hornick RB, Woodward TE. Histopathology of the upper small intestines in typhoid fever. Biopsy study of experimental disease in man. *Am. J. Dig. Dis.* 1966; 11:615–624. [PubMed: 5943767]



17. Cornes JS. Number, size, and distribution of Peyer's patches in the human small intestine: Part I The development of Peyer's patches. *Gut*. 1965; 6:225–229. [PubMed: 18668776]
18. Cornes JS. Peyer's patches in the human gut. *Proc. R. Soc. Med.* 1965; 58:716.
19. Schulz O, Pabst O. Antigen sampling in the small intestine. *Trends Immunol.* 2013; 34:155–161. [PubMed: 23083727]
20. Hallback DA, Hulten L, Jodal M, Lindhagen J, Lundgren O. Evidence for the existence of a countercurrent exchanger in the small intestine in man. *Gastroenterology*. 1978; 74:683–690. [PubMed: 631505]
21. Hallback DA, Jodal M, Mannischeff M, Lundgren O. Tissue osmolality in intestinal villi of four mammals in vivo and in vitro. *Acta Physiol. Scand.* 1991; 143:271–277. [PubMed: 1772035]
22. Zhou D, Galan J. *Salmonella* entry into host cells: the work in concert of type III secreted effector proteins. *Microbes and infection / Institut Pasteur*. 2001; 3:1293–1298.
23. Kuhle V, Hensel M. Cellular microbiology of intracellular *Salmonella enterica*: functions of the type III secretion system encoded by *Salmonella* pathogenicity island 2. *Cell. Mol. Life Sci.* 2004; 61:2812–2826. [PubMed: 15558211]
24. Winter SE, Winter MG, Godinez I, Yang HJ, Russmann H, Andrews-Polymeris HL, Baumler AJ. A rapid change in virulence gene expression during the transition from the intestinal lumen into tissue promotes systemic dissemination of *Salmonella*. *PLoS Pathog.* 2010; 6:e1001060. [PubMed: 20808848]
25. Dagan T, Blekhan R, Graur D. The "domino theory" of gene death: gradual and mass gene extinction events in three lineages of obligate symbiotic bacterial pathogens. *Mol. Biol. Evol.* 2006; 23:310–316. [PubMed: 16237210]
26. Parkhill J, Dougan G, James KD, Thomson NR, Pickard D, Wain J, Churcher C, Mungall KL, Bentley SD, Holden MTG, Sebaihia M, Baker S, Basham D, Brooks K, Chillingworth T, Connor P, Cronin A, Davis P, Davies RM, Dowd L, White N, Farrar J, Feltwell T, Hamlin N, Haque A, Hien TT, Holroyd S, Jagels K, Krogh A, Larsen TS, Leather S, Moule S, O'Gaora P, Parry C, Quail M, Rutherford K, Simmonds M, Skelton J, Stevens K, Whitehead S, Barrell BG. Complete genome sequence of a multiple drug resistant *Salmonella enterica* serovar Typhi CT18. *Nature*. 2001; 413:848–852. [PubMed: 11677608]
27. Winter SE, Thiennimitr P, Winter MG, Butler BP, Huseby DL, Crawford RW, Russell JM, Bevins CL, Adams LG, Tsolis RM, Roth JR, Baumler AJ. Gut inflammation provides a respiratory electron acceptor for *Salmonella*. *Nature*. 2010; 467:426–429. [PubMed: 20864996]
28. Rivera-Chavez F, Baumler AJ. The pyromaniac inside you: *Salmonella* metabolism in the host gut. *Annu. Rev. Microbiol.* 2015; 69:31–48. [PubMed: 26002180]
29. Nuccio SP, Baumler AJ. Comparative analysis of *Salmonella* genomes identifies a metabolic network for escalating growth in the inflamed gut. *mBio*. 2014; 5:e00929–e00914. [PubMed: 24643865]
30. Seth-Smith HM. SPI-7: *Salmonella*'s Vi-encoding pathogenicity island. *Journal of infection in developing countries*. 2008; 2:267–271. [PubMed: 19741287]
31. Winter SE, Winter MG, Thiennimitr P, Gerriets VA, Nuccio SP, Russmann H, Baumler AJ. The TviA auxiliary protein renders the *Salmonella enterica* serotype Typhi RcsB regulon responsive to changes in osmolarity. *Mol. Microbiol.* 2009; 74:175–193. [PubMed: 19703107]
32. Tran QT, Gomez G, Khare S, Lawhon SD, Raffatellu M, Baumler AJ, Ajithdoss D, Dhavala S, Adams LG. The *Salmonella enterica* serotype Typhi Vi capsular antigen is expressed after the bacterium enters the ileal mucosa. *Infect. Immun.* 2010; 78:527–535. [PubMed: 19901065]
33. Wilson RP, Raffatellu M, Chessa D, Winter SE, Tukel C, Baumler AJ. The Vi-capsule prevents Toll-like receptor 4 recognition of *Salmonella*. *Cell. Microbiol.* 2008; 10:876–890.
34. Crawford RW, Wangdi T, Spees AM, Xavier MN, Tsolis RM, Baumler AJ. Loss of very-long O-antigen chains optimizes capsule-mediated immune evasion by *Salmonella enterica* serovar Typhi. *mBio*. 2013; 4
35. Wangdi T, Lee CY, Spees AM, Yu C, Kingsbury DD, Winter SE, Haste CJ, Wilson RP, Heinrich V, Baumler AJ. The Vi capsular polysaccharide enables *Salmonella enterica* serovar typhi to evade microbe-guided neutrophil chemotaxis. *PLoS Pathog.* 2014; 10:e1004306. [PubMed: 25101794]


36. Gewirtz AT, Navas TA, Lyons S, Godowski PJ, Madara JL. Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. *J. Immunol.* 2001; 167:1882–1885. [PubMed: 11489966]
37. Abreu MT. Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. *Nat. Rev. Immunol.* 2010; 10:131–144. [PubMed: 20098461]
38. Winter SE, Winter MG, Atluri V, Poon V, Romao EL, Tsolis RM, Baumler AJ. The flagellar regulator TviA reduces pyroptosis by *Salmonella enterica* serovar Typhi. *Infect. Immun.* 2015; 83:1546–1555. [PubMed: 25644011]
39. WHO. Geneva, Switzerland: World Health Organization; 2003. Background document: The diagnosis, treatment, and prevention of typhoid fever.
40. Schwan WR, Huang XZ, Hu L, Kopecko DJ. Differential bacterial survival, replication, and apoptosis-inducing ability of *Salmonella* serovars within human and murine macrophages. *Infect. Immun.* 2000; 68:1005–1013. [PubMed: 10678900]
41. Darton TC, Jones C, Waddington CS, Dougan G, Szein M, Levine M, Angus B, Farrar J, Lockhart S, Crook D, Pollard AJ, Zhou L. Demonstration of primary and asymptomatic DNAemia in participants challenged with *Salmonella* Typhi (Quailles strain) during the development of a human model of typhoid infection. *Int. J. Infect. Dis.* 2012; 16S:e215.
42. Rubin FA, McWhirter PD, Burr D, Punjabi NH, Lane E, Kumala S, Sudarmono P, Pulungsih SP, Lesmana M, Tjaniadi P, et al. Rapid diagnosis of typhoid fever through identification of *Salmonella typhi* within 18 hours of specimen acquisition by culture of the mononuclear cell-platelet fraction of blood. *J. Clin. Microbiol.* 1990; 28:825–827. [PubMed: 2332479]
43. Wain J, Diep TS, Ho VA, Walsh AM, Nguyen TT, Parry CM, White NJ. Quantitation of bacteria in blood of typhoid fever patients and relationship between counts and clinical features, transmissibility, and antibiotic resistance. *J. Clin. Microbiol.* 1998; 36:1683–1687. [PubMed: 9620400]
44. Wain J, Pham VB, Ha V, Nguyen NM, To SD, Walsh AL, Parry CM, Hasserjian RP, HoHo VA, Tran TH, Farrar J, White NJ, Day NP. Quantitation of bacteria in bone marrow from patients with typhoid fever: relationship between counts and clinical features. *J. Clin. Microbiol.* 2001; 39:1571–1576. [PubMed: 11283089]
45. Everest P, Wain J, Roberts M, Rook G, Dougan G. The molecular mechanisms of severe typhoid fever. *Trends Microbiol.* 2001; 9:316–320. [PubMed: 11435104]
46. Dougan G, Baker S. *Salmonella enterica* serovar Typhi and the pathogenesis of typhoid fever. *Annu. Rev. Microbiol.* 2014; 68:317–336. [PubMed: 25208300]
47. Ramsey GH. What Are the Essentials of Typhoid Fever Control Today? *Am. J. Public Health Nations Health.* 1934; 24:355–362. [PubMed: 18013972]
48. Anderson GW, Hamblen AD, Smith HM. Typhoid Carriers -A Study of Their Disease Producing Potentialities Over a Series of Years as Indicated by a Study of Cases. *Am. J. Public Health Nations Health.* 1936; 26:396–405. [PubMed: 18014409]
49. Merselis JG Jr, Kaye D, Connolly CS, Hook EW. Quantitative bacteriology of the typhoid carrier state. *Am. J. Trop. Med. Hyg.* 1964; 13:425–429. [PubMed: 14159980]
50. Marshall JM, Flechtner AD, La Perle KM, Gunn JS. Visualization of extracellular matrix components within sectioned *Salmonella* biofilms on the surface of human gallstones. *PLoS One.* 2014; 9:e89243. [PubMed: 24551241]
51. Knodler LA, Vallance BA, Celli J, Winfree S, Hansen B, Montero M, Steele-Mortimer O. Dissemination of invasive *Salmonella* via bacterial-induced extrusion of mucosal epithelia. *Proc. Natl. Acad. Sci. U. S. A.* 2010; 107:17733–17738. [PubMed: 20876119]
52. Gonzalez-Escobedo G, Marshall JM, Gunn JS. Chronic and acute infection of the gall bladder by *Salmonella typhi*: understanding the carrier state. *Nature reviews. Microbiology.* 2011; 9:9–14. [PubMed: 21113180]
53. Felix A. Detection of chronic typhoid carriers by agglutination tests. *Lancet Infect. Dis.* 1938; ii: 738–741.
54. Lanata CF, Levine MM, Ristori C, Black RE, Jimenez L, Salcedo M, Garcia J, Sotomayor V. Vi serology in detection of chronic *Salmonella typhi* carriers in an endemic area. *Lancet.* 1983; 2:441–443. [PubMed: 6192305]

55. van Basten JP, Stockenbrugger R. Typhoid perforation. A review of the literature since 1960. *Trop. Geogr. Med.* 1994; 46:336–339. [PubMed: 7892698]
56. Mogasale V, Desai SN, Mogasale VV, Park JK, Ochiai RL, Wierzba TF. Case fatality rate and length of hospital stay among patients with typhoid intestinal perforation in developing countries: a systematic literature review. *PLoS One.* 2014; 9:e93784. [PubMed: 24743649]
57. Archampong EQ. Operative treatment of typhoid perforation of the bowel. *Br. Med. J.* 1969; 3:273–276. [PubMed: 5800367]
58. Sheikh A, Bhuiyan MS, Khanam F, Chowdhury F, Saha A, Ahmed D, Jamil KM, LaRocque RC, Harris JB, Ahmad MM, Charles R, Brooks WA, Calderwood SB, Cravioto A, Ryan ET, Qadri F. *Salmonella enterica* serovar Typhi-specific immunoglobulin A antibody responses in plasma and antibody in lymphocyte supernatant specimens in Bangladeshi patients with suspected typhoid fever. *Clin. Vaccine Immunol.* 2009; 16:1587–1594. [PubMed: 19741090]
59. Khanam F, Sayeed MA, Choudhury FK, Sheikh A, Ahmed D, Goswami D, Hossain ML, Brooks A, Calderwood SB, Charles RC, Cravioto A, Ryan ET, Qadri F. Typhoid fever in young children in Bangladesh: clinical findings, antibiotic susceptibility pattern and immune responses. *PLoS Negl. Trop. Dis.* 2015; 9:e0003619. [PubMed: 25849611]
60. Sheikh A, Khanam F, Sayeed MA, Rahman T, Pacek M, Hu Y, Rollins A, Bhuiyan MS, Rollins S, Kalsy A, Arifuzzaman M, Leung DT, Sarracino DA, Krastins B, Charles RC, Larocque RC, Cravioto A, Calderwood SB, Brooks WA, Harris JB, Labaer J, Qadri F, Ryan ET. Interferon-gamma and proliferation responses to *Salmonella enterica* serotype Typhi proteins in patients with *S*Typhi Bacteremia in Dhaka, Bangladesh. *PLoS Negl. Trop. Dis.* 2011; 5:e1193. [PubMed: 21666798]
61. Shi H, Santander J, Brennehan KE, Wanda SY, Wang S, Senechal P, Sun W, Roland KL, Curtiss R. Live recombinant *Salmonella* Typhi vaccines constructed to investigate the role of *rpoS* in eliciting immunity to a heterologous antigen. *PLoS One.* 2010; 5:e11142. [PubMed: 20585446]
62. Bhuiyan S, Sayeed A, Khanam F, Leung DT, Rahman Bhuiyan T, Sheikh A, Salma U, LaRocque RC, Harris JB, Pacek M, Calderwood SB, LaBaer J, Ryan ET, Qadri F, Charles RC. Cellular and cytokine responses to *Salmonella enterica* serotype Typhi proteins in patients with typhoid fever in Bangladesh. *Am. J. Trop. Med. Hyg.* 2014; 90:1024–1030. [PubMed: 24615129]
63. de Wit J, Souwer Y, Jorritsma T, Klaasse Bos H, ten Brinke A, Neeffjes J, van Ham SM. Antigen-specific B cells reactivate an effective cytotoxic T cell response against phagocytosed *Salmonella* through cross-presentation. *PLoS One.* 2010; 5:e13016. [PubMed: 20885961]
64. McArthur MA, Sztejn MB. Heterogeneity of multifunctional IL-17A producing *S*Typhi-specific CD8+ T cells in volunteers following Ty21a typhoid immunization. *PLoS One.* 2012; 7:e38408. [PubMed: 22679502]
65. McArthur MA, Fresnay S, Magder LS, Darton TC, Jones C, Waddington CS, Blohmke CJ, Dougan G, Angus B, Levine MM, Pollard AJ, Sztejn MB. Activation of *Salmonella* Typhi-specific regulatory T cells in typhoid disease in a wild-type *S*Typhi challenge model. *PLoS Pathog.* 2015; 11:e1004914. [PubMed: 26001081]
66. Ravindran R, McSorley SJ. Tracking the dynamics of T-cell activation in response to *Salmonella* infection. *Immunology.* 2005; 114:450–458. [PubMed: 15804280]
67. Germanier R, Fuer E. Isolation and characterization of *galE* mutant Ty 21a of *Salmonella typhi*: a candidate strain for a live, oral typhoid vaccine. *J. Infect. Dis.* 1975; 131:553–558. [PubMed: 1092768]
68. Schendel PF, Michaeli I. A model for the mechanism of alkylation mutagenesis. *Mutat. Res.* 1984; 125:1–14. [PubMed: 6690908]
69. Kopecko DJ, Sieber H, Ures JA, Furer A, Schlup J, Knof U, Collioud A, Xu D, Colburn K, Dietrich G. Genetic stability of vaccine strain *Salmonella* Typhi Ty21a over 25 years. *Int. J. Med. Microbiol.* 2009; 299:233–246. [PubMed: 19121604]
70. Gilman RH, Hornick RB, Woodard WE, DuPont HL, Snyder MJ, Levine MM, Libonati JP. Evaluation of a UDP-glucose-4-epimeraseless mutant of *Salmonella typhi* as a liver oral vaccine. *J. Infect. Dis.* 1977; 136:717–723. [PubMed: 925379]

71. Levine MM, Ferreccio C, Abrego P, Martin OS, Ortiz E, Cryz S. Duration of efficacy of Ty21a, attenuated *Salmonella typhi* live oral vaccine. *Vaccine*. 1999; 17(Suppl 2):S22–S27. [PubMed: 10506405]
72. Marmion DE, Naylor GR, Stewart IO. Second attacks of typhoid fever. *J. Hyg. (Lond.)*. 1953; 51:260–267. [PubMed: 13069708]
73. Dupont HL, Hornick RB, Snyder MJ, Dawkins AT, Heiner GG, Woodward TE. Studies of immunity in typhoid fever. Protection induced by killed oral antigens or by primary infection. *Bull. World Health Organ.* 1971; 44:667–672. [PubMed: 5316750]
74. Otczyk DC, Cripps AW. Mucosal immunization: a realistic alternative. *Human vaccines*. 2010; 6:978–1006. [PubMed: 21150284]
75. Wahid R, Zafar SJ, McArthur MA, Pasetti MF, Levine MM, Sztein MB. Live oral *Salmonella enterica* serovar Typhi vaccines Ty21a and CVD 909 induce opsonophagocytic functional antibodies in humans that cross-react with *S*Paratyphi A and *S*Paratyphi B. *Clin. Vaccine Immunol.* 2014; 21:427–434. [PubMed: 24429069]
76. Kantele A, Kantele JM, Savilahti E, Westerholm M, Arvilommi H, Lazarovits A, Butcher EC, Makela PH. Homing potentials of circulating lymphocytes in humans depend on the site of activation: oral, but not parenteral, typhoid vaccination induces circulating antibody-secreting cells that all bear homing receptors directing them to the gut. *J. Immunol.* 1997; 158:574–579. [PubMed: 8992970]
77. Wahid R, Pasetti MF, Maciel M Jr, Simon JK, Tacket CO, Levine MM, Sztein MB. Oral priming with *Salmonella* Typhi vaccine strain CVD 909 followed by parenteral boost with the *S* Typhi Vi capsular polysaccharide vaccine induces CD27+IgD-*S* Typhi-specific IgA and IgG B memory cells in humans. *Clin. Immunol.* 2011; 138:187–200. [PubMed: 21146460]
78. Tagliabue A, Villa L, DeMagistiris MT, Romano M, Silvestri S, Boraschji D, Nencioni L. IgA-driven T-cell-mediated antibacterial immunity in man after live oral Ty21a vaccine. *J. Immunol.* 1986; 137:1504–1510. [PubMed: 3489034]
79. Wahid R, Salerno-Goncalves R, Tacket CO, Levine MM, Sztein MB. Generation of specific effector and memory T cells with gut- and secondary lymphoid tissue- homing potential by oral attenuated CVD 909 typhoid vaccine in humans. *Mucosal. Immunol.* 2008; 1:389–398. [PubMed: 19079203]
80. Wyant TL, Tanner MK, Sztein MB. *Salmonella typhi* flagella are potent inducers of proinflammatory cytokine secretion by human monocytes. *Infect. Immun.* 1999; 67:3619–3624. [PubMed: 10377147]
81. Tagliabue A, Nencioni L, Caffarena A, Villa L, Boraschi D, Cazzola G, Cavaliere S. Cellular immunity against *Salmonella typhi* after live oral vaccine. *Clin. Exp. Immunol.* 1985; 62:242–247. [PubMed: 3878744]
82. Lundin BS, Johansson C, Svennerholm AM. Oral immunization with a *Salmonella enterica* serovar typhi vaccine induces specific circulating mucosa-homing CD4(+) and CD8(+) T cells in humans. *Infect. Immun.* 2002; 70:5622–5627. [PubMed: 12228290]
83. Salerno-Goncalves R, Pasetti MF, Sztein MB. Characterization of CD8(+) effector T cell responses in volunteers immunized with *Salmonella enterica* serovar Typhi strain Ty21a typhoid vaccine. *J Immunol.* 2002; 169:2196–2203. [PubMed: 12165550]
84. Salerno-Goncalves R, Wahid R, Sztein MB. Immunization of volunteers with *Salmonella enterica* serovar Typhi strain Ty21a elicits the oligoclonal expansion of CD8+ T cells with predominant Vbeta repertoires. *Infect. Immun.* 2005; 73:3521–3530. [PubMed: 15908381]
85. Salerno-Goncalves R, Wahid R, Sztein MB. Ex vivo kinetics of early and long-term multifunctional human leukocyte antigen E-specific CD8+ cells in volunteers immunized with the Ty21a typhoid vaccine. *Clin. Vaccine Immunol.* 2010; 17:1305–1314. [PubMed: 20660136]
86. Robbe-Saule V, Algorta G, Rouilhac I, Norel F. Characterization of the RpoS status of clinical isolates of *Salmonella enterica*. *Appl. Environ. Microbiol.* 2003; 69:4352–4358. [PubMed: 12902215]
87. Santander J, Wanda SY, Nickerson CA, Curtiss R 3rd. Role of RpoS in fine-tuning the synthesis of Vi capsular polysaccharide in *Salmonella enterica* serotype Typhi. *Infect. Immun.* 2007; 75:1382–1392. [PubMed: 17178790]


88. Santander J, Roland KL, Curtiss R 3rd. Regulation of Vi capsular polysaccharide synthesis in *Salmonella enterica* serotype Typhi. *Journal of infection in developing countries*. 2008; 2:412–420. [PubMed: 19745516]
89. Wain J, House D, Zafar A, Baker S, Nair S, Kidgell C, Bhutta Z, Dougan G, Hasan R. Vi antigen expression in *Salmonella enterica* serovar Typhi clinical isolates from Pakistan. *J. Clin. Microbiol.* 2005; 43:1158–1165. [PubMed: 15750077]
90. Frey SE, Lottenbach KR, Hill H, Blevins TP, Yu Y, Zhang Y, Bresnahan PA, Kelly-Aehle SM, Jansen A, Curtiss R Iii. A Phase 1 dose-escalation trial in adults of three recombinant attenuated *Salmonella* Typhi vaccine vectors producing *Streptococcus pneumoniae* surface protein antigen PspA. *Vaccine*. 2013; 31:4874–4880. [PubMed: 23916987]
91. Fass E, Groisman EA. Control of *Salmonella* pathogenicity island-2 gene expression. *Curr. Opin. Microbiol.* 2009; 12:199–204. [PubMed: 19264535]
92. Sabbagh SC, Forest CG, Lepage C, Leclerc JM, Daigle F. So similar, yet so different: uncovering distinctive features in the genomes of *Salmonella enterica* serovars Typhimurium and Typhi. *FEMS Microbiol. Lett.* 2010; 305:1–13. [PubMed: 20146749]
93. Miller VL, Beer KB, Loomis WP, Olson JA, Miller SI. An unusual *pagC*::Tn *phoA* mutation leads to an invasion- and virulence-defective phenotype in Salmonellae. *Infect. Immun.* 1992; 60:3763–3770. [PubMed: 1323535]
94. Hohmann EL, Oletta CA, Killeen KP, Miller SI. *phoP/phoQ*-deleted *Salmonella typhi* (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. *J. Infect. Dis.* 1996; 173:1408–1414. [PubMed: 8648213]
95. DiPetrillo MD, Tibbetts T, Kleanthous H, Killeen KP, Hohmann EL. Safety and immunogenicity of *phoP/phoQ*-deleted *Salmonella typhi* expressing *Helicobacter pylori* urease in adult volunteers. *Vaccine*. 1999; 18:449–459. [PubMed: 10519934]
96. Angelakopoulos H, Hohmann EL. Pilot study of *phoP/phoQ*-deleted *Salmonella enterica* serovar typhimurium expressing *Helicobacter pylori* urease in adult volunteers. *Infect. Immun.* 2000; 68:2135–2141. [PubMed: 10722611]
97. Hindle Z, Chatfield SN, Phillimore J, Bentley M, Johnson J, Cosgrove CA, Ghaem-Maghami M, Sexton A, Khan M, Brennan FR, Everest P, Wu T, Pickard D, Holden DW, Dougan G, Griffin GE, House D, Santangelo JD, Khan SA, Shea JE, Feldman RG, Lewis DJ. Characterization of *Salmonella enterica* derivatives harboring defined *aroC* and *Salmonella* pathogenicity island 2 type III secretion system (*ssaV*) mutations by immunization of healthy volunteers. *Infect. Immun.* 2002; 70:3457–3467. [PubMed: 12065485]
98. Pittard, AJ. Biosynthesis of the aromatic amino acids. In: Neidhardt, FC.; Curtiss, R., Iii; Ingraham, JL.; Lin, ECC.; Low, KB.; Magasanik, B.; Reznikoff, WS.; Riley, M.; Schaechter, M.; Umberger, HE., editors. *Escherichia coli and Salmonella : cellular and molecular biology*. Vol. 2. Washington, D.C.: ASM Press; 1996. p. 458-484.
99. Kirkpatrick BD, Tenney KM, Larsson CJ, O'Neill JP, Ventrone C, Bentley M, Upton A, Hindle Z, Fidler C, Kutzko D, Holdridge R, Lapointe C, Hamlet S, Chatfield SN. The novel oral typhoid vaccine M01ZH09 is well tolerated and highly immunogenic in 2 vaccine presentations. *J. Infect. Dis.* 2005; 192:360–366. [PubMed: 15995948]
100. Kirkpatrick BD, McKenzie R, O'Neill JP, Larsson CJ, Bourgeois AL, Shimko J, Bentley M, Makin J, Chatfield S, Hindle Z, Fidler C, Robinson BE, Ventrone CH, Bansal N, Carpenter CM, Kutzko D, Hamlet S, LaPointe C, Taylor DN. Evaluation of *Salmonella enterica* serovar Typhi (Ty2*aroC*-*ssaV*) M01ZH09, with a defined mutation in the *Salmonella* pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers. *Vaccine*. 2006; 24:116–123. [PubMed: 16140433]
101. Tran TH, Nguyen TD, Nguyen TT, Ninh TT, Tran NB, Nguyen VM, Tran TT, Cao TT, Pham VM, Nguyen TC, Tran TD, Pham VT, To SD, Campbell JI, Stockwell E, Schultsz C, Simmons CP, Glover C, Lam W, Marques F, May JP, Upton A, Budhram R, Dougan G, Farrar J, Nguyen VV, Dolecek C. A randomised trial evaluating the safety and immunogenicity of the novel single oral dose typhoid vaccine M01ZH09 in healthy Vietnamese children. *PLoS One*. 2010; 5:e11778. [PubMed: 20668668]
102. Lyon CE, Sadigh KS, Carmolli MP, Harro C, Sheldon E, Lindow JC, Larsson CJ, Martinez T, Feller A, Ventrone CH, Sack DA, DeNearing B, Fingar A, Pierce K, Dill EA, Schwartz HI,

- Beardsworth EE, Kilonzo B, May JP, Lam W, Upton A, Budhram R, Kirkpatrick BD. In a randomized, double-blinded, placebo-controlled trial, the single oral dose typhoid vaccine, MO1ZH09, is safe and immunogenic at doses up to  $1.7 \times 10^{10}$  colony-forming units. *Vaccine*. 2010; 28:3602–3608. [PubMed: 20188175]
103. Tacket CO, Hone DM, Losonsky GA, Guers L, Edelman R, Levine MM. Clinical acceptability and immunogenicity of CVD 908 *Salmonella typhi* vaccine strain. *Vaccine*. 1992; 10:443–446. [PubMed: 1609547]
104. Sztejn MB, Wasserman SS, Tacket CO, Edelman R, Hone D, Lindberg AA, Levine MM. Cytokine production patterns and lymphoproliferative responses in volunteers orally immunized with attenuated vaccine strains of *Salmonella typhi*. *J Infect. Dis*. 1994; 170:1508–1517. [PubMed: 7995991]
105. Tacket CO, Sztejn M, Losonsky G, Wasserman SS, Nataro JP, Edelman R, Pickard D, Dougan G, Chatfield S, Levine MM. Safety of live oral *Salmonella typhi* vaccine strains with deletions in *htrA* and *aroC aroD* and immune responses in humans. *Infect. Immun*. 1997; 65:452–456. [PubMed: 9009296]
106. Baumler AJ, Kusters JG, Stojiljkovic I, Heffron F. *Salmonella typhimurium* loci involved in survival within macrophages. *Infect. Immun*. 1994; 62:1623–1630. [PubMed: 8168923]
107. Tacket CO, Sztejn M, Wasserman SS, Losonsky G, Kotloff K, Wyant TL, Nataro JP, Edelman R, Perry JG, Bedford P, Brown D, Chatfield S, Dougan G, Levine MM. Phase 2 clinical trial of attenuated *Salmonella enterica* serovar Typhi oral live vector vaccine CVD 908-*htrA* in U.S. volunteers. *Infect. Immun*. 2000; 68:1196–1201. [PubMed: 10678926]
108. Wang JY, Noriega F, Galen JE, Barry EM, Levine MM. Constitutive expression of the Vi polysaccharide capsular antigen in attenuated *Salmonella enterica* serovar Typhi oral vaccine strain CVD 909. *Infect. Immun*. 2000; 68:4647–4652. [PubMed: 10899868]
109. Zhao L, Ezak T, Li ZY, Kawamura Y, Hirose K, Watanabe H. Vi-Suppressed wild strain *Salmonella typhi* cultured in high osmolarity is hyperinvasive toward epithelial cells and destructive of Peyer's patches. *Microbiol. Immunol*. 2001; 45:149–158. [PubMed: 11293481]
110. Tacket CO, Pasetti MF, Sztejn MB, Livio S, Levine MM. Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide. *J. Infect. Dis*. 2004; 190:565–570. [PubMed: 15243933]
111. Okoro CK, Kingsley RA, Connor TR, Harris SR, Parry CM, Al-Mashhadani MN, Kariuki S, Msefula CL, Gordon MA, de Pinna E, Wain J, Heyderman RS, Obaro S, Alonso PL, Mandomando I, MacLennan CA, Tapia MD, Levine MM, Tennant SM, Parkhill J, Dougan G. Intracontinental spread of human invasive *Salmonella* Typhimurium pathovariants in sub-Saharan Africa. *Nat. Genet*. 2012; 44:1215–1221. [PubMed: 23023330]
112. Ao TT, Feasey NA, Gordon MA, Keddy KH, Angulo FJ, Crump JA. Global burden of invasive nontyphoidal *Salmonella* disease, 2010(1). *Emerg. Infect. Dis*. 2015; 21
113. Kingsley RA, Msefula CL, Thomson NR, Kariuki S, Holt KE, Gordon MA, Harris D, Clarke L, Whitehead S, Sangal V, Marsh K, Achtman M, Molyneux ME, Cormican M, Parkhill J, MacLennan CA, Heyderman RS, Dougan G. Epidemic multiple drug resistant *Salmonella* Typhimurium causing invasive disease in sub-Saharan Africa have a distinct genotype. *Genome Res*. 2009; 19:2279–2287. [PubMed: 19901036]
114. Ramachandran G, Perkins DJ, Schmidlein PJ, Tulapurkar ME, Tennant SM. Invasive *Salmonella* Typhimurium ST313 with naturally attenuated flagellin elicits reduced inflammation and replicates within macrophages. *PLoS Negl. Trop. Dis*. 2015; 9:e3394. [PubMed: 25569606]
115. Herrero-Fresno A, Wallrodt I, Leekitcharoenphon P, Olsen JE, Aarestrup FM, Hendriksen RS. The role of the *st313-td* gene in virulence of *Salmonella* Typhimurium ST313. *PLoS One*. 2014; 9:e84566. [PubMed: 24404174]



**Figure 1. Pathobiology of human *Salmonella* infections**

Infection with *Salmonella* is initiated following oral ingestion of contaminated food or water (A). *Salmonella* must then overcome potentially lethal levels of inorganic acid (H<sup>+</sup>) which produce pHs as low as 2 in the stomach of healthy adults (B). *Salmonella* organisms surviving the extreme acidic conditions of the stomach eventually drain into the small intestine, the portal for invasion into deeper tissues and development of systemic disease (C). *Salmonella* invade tissues of both villus epithelial tissue as well as lymphoid Peyer's patches. Following transit of invading *Salmonella* out of the lumen and across the epithelial barrier of the small intestine, bacteria eventually gain transient access to the bloodstream to eventually colonize deep tissues including the liver (D), spleen, and bone marrow. It is at this stage that infection with *S. Typhimurium* is typically halted, and does not progress to systemic disease in immunologically competent humans. However, *S. Typhi* can be released from deep tissues back into the bloodstream, triggering a more substantial secondary bacteremia which precedes the onset of classic typhoid fever. In rare cases, typhoid fever can progress to an asymptomatic chronic infection in which *S. Typhi* can migrate down the hepatic ducts of the liver and into the gall bladder (E), setting up a convalescent carrier state in which very high levels of organisms can be intermittently released back into the small intestine, passing through the large intestine (F) and being released in the feces (G).



**Figure 2. Induction of villus invasion by *Salmonella***

Invasion of *Salmonella* into deeper tissues of the human host occurs primarily in the small intestine (A) and is triggered by environmental signals including osmolarity. Villi of the small intestine possess a gradient of osmolarity which is highest at the luminal surface of villi and decreases to physiological osmolarity in the lower crypts of the villus. Incoming luminal *Salmonella* sense the high osmolarity of villus surfaces which induce invasion (B). High osmolarity in the lumen up-regulates *rpoS*, which in turn represses synthesis of Vi in *S. Typhi* to enhance invasion; this negative control is further strengthened by the osmotic



repression of *tviA* which is a positive activator of Vi synthesis (C). In addition, high osmolarity signals OmpR to up-regulate *Salmonella* Pathogenicity Island 1 (SPI-1) to inject effector proteins into target eukaryotic cells, resulting in ruffling of the outer membrane and engulfment of invading bacteria. Transepithelial migration then reduces the osmolarity to physiological levels, repressing *rpoS* and activating *tviA* for induction of Vi synthesis. TviA is also a repressor of flagellar synthesis; therefore, *S. Typhi* is motile in the intestinal lumen when TviA is repressed (panel C, top left), but replaces flagella with the Vi capsule upon entry into host tissue (panel C, bottom left).

**Table 1**

Selected candidate live oral *Salmonella* vaccines against human disease tested in Phase 1/Phase 2 clinical trials.

Attenuation strategy	Vaccine strain	Serovar; strain; relevant genotype	Relevant phenotype	Ref
<b>Chemical mutagenesis</b>	Ty21a	Typhi; Ty2; <i>rpoS galE galK ilvD vexD</i>	Natural RpoS-dependent sensitivity to environmental stressors; defective synthesis of LPS; auxotrophic for isoleucine and valine; defective synthesis of Vi	(69)
<b>Engineered deletions in <i>rpoS</i></b>	$\chi$ 9639 <sup>*</sup>	Typhi; Ty2; <i>rpoS</i>	Natural RpoS-dependent sensitivity to environmental stressors	(90)
	$\chi$ 9640 <sup>*</sup>	Typhi; Ty2; <i>rpoS+</i>	Engineered RpoS-mediated resistance to environmental stressors	(90)
	$\chi$ 9633 <sup>*</sup>	Typhi; ISP1820; <i>rpoS+</i>	Natural RpoS-mediated resistance to environmental stressors	(90)
<b>Engineered deletions in <i>phoP/phoQ</i></b>	Ty800	Typhi; Ty2; <i>rpoS phoP phoQ</i>	Natural RpoS-dependent sensitivity to environmental stressors; defective in pH and osmolarity induction of invasion virulence factors	(94)
	Ty1033 <sup>‡</sup>	Typhi; Ty2; <i>rpoS phoP phoQ</i>	Natural RpoS-dependent sensitivity to environmental stressors; defective in pH and osmolarity induction of invasion virulence factors	(96)
	LH1160 <sup>‡</sup>	<b>Typhimurium;</b> <b>ATCC 14028;</b> <i>phoP phoQ</i>	Defective in pH and osmolarity induction of invasion virulence factors	(95)
<b>Engineered deletions in <i>ssaV</i></b>	M01ZH09	Typhi; Ty2; <i>rpoS aroC ssaV</i>	Natural RpoS-dependent sensitivity to environmental stressors; auxotrophic for aromatic amino acids; defective for proper secretion of SPI-2 effector proteins	(97) (99, 100) (101) (102)
	WT05	<b>Typhimurium;</b> <b>TML;</b> <i>aroC ssaV</i>	Auxotrophic for aromatic amino acids; defective for proper secretion of SPI-2 effector proteins	(97)
<b>Engineered deletions in <i>aroC, aroD, and htrA</i></b>	CVD 908	Typhi; Ty2; <i>rpoS aroC aroD</i>	Natural RpoS-dependent sensitivity to environmental stressors; auxotrophic for aromatic amino acids	(105)
	CVD 908- <i>htrA</i>	Typhi; Ty2; <i>rpoS aroC aroD htrA</i>	Natural RpoS-dependent sensitivity to environmental stressors; auxotrophic for aromatic amino acids; sensitive to environmental heat shock	(107)
	CVD 909	Typhi; Ty2; <i>rpoS<sub>P<sub>tac</sub>-tviA</sub></i> aroC aroD htrA	Natural RpoS-dependent sensitivity to environmental stressors; constitutive expression of TviA regulator and Vi antigen; auxotrophic for aromatic amino acids; sensitive to environmental heat shock	(77) (108) (110)

<sup>\*</sup> These vaccines were engineered as live vector vaccines, carrying additional chromosomal mutations, as well as also carrying multicopy plasmids expressing a pneumococcal foreign antigen. However, all candidate vaccines carried the same attenuating lesions and differed only with respect to parental strain used (Ty2 vs ISP1820) and the presence of *rpoS*.

<sup>‡</sup> These vaccines were engineered as live vector vaccines, carrying one additional chromosomal deletion in the *purB* gene, as well as also carrying multicopy plasmids encoding both *purB* and the foreign antigen urease from *Helicobacter pylori*. However, both *S. Typhi* and *S. Typhimurium* candidate vaccines were isogenic for the attenuating lesions tested in clinical trials.